Literature DB >> 24659875

Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Umberto Vespasiani-Gentilucci1, Paolo Gallo1, Antonio De Vincentis1, Giovanni Galati1, Antonio Picardi1.   

Abstract

Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide, and alterations of glucose metabolism have reached pandemic proportions in western countries. However, the frequent coexistence between these two conditions is more than simply coincidental, since HCV can induce insulin resistance through several mechanisms. Indeed, the virus interferes with insulin signaling both directly and indirectly, inducing the production of pro-inflammatory cytokines. Furthermore, the entire viral life cycle has strict interconnections with lipid metabolism, and HCV is responsible for a "viral" steatosis which is frequently superimposed to a "metabolic" one. Several evidences suggest that HCV-induced metabolic disorders contribute both to the evolution of liver fibrosis and, likely, to the progression of the other disorders which are typically associated with altered metabolism, in particular atherosclerosis. In the present review, we will examine in depth the links between HCV infection and insulin resistance, liver steatosis and diabetes, and analyze the impact of these interactions on the progression of liver fibrosis and atherosclerosis. Special attention will be focused on the highly debated topic of the relationship between HCV infection and cardiovascular disease. The available clinical literature on this item will be broadly reviewed and all the mechanisms possibly implied will be discussed.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular risk; Diabetes mellitus; Fibrosis; Hepatitis C virus; Insulin resistance; Metabolism; Steatosis

Mesh:

Year:  2014        PMID: 24659875      PMCID: PMC3961987          DOI: 10.3748/wjg.v20.i11.2825

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  132 in total

1.  Hepatitis C virus and atherosclerosis in patients with type 2 diabetes.

Authors:  Michiaki Fukui; Yoshihiro Kitagawa; Naoto Nakamura; Toshikazu Yoshikawa
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

2.  Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.

Authors:  G Perseghin; V Mazzaferro; L P Sereni; E Regalia; S Benedini; E Bazzigaluppi; A Pulvirenti; A A Leão; G Calori; R Romito; D Baratti; L Luzi
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells.

Authors:  Hisashi Ishida; Kui Li; Minkyung Yi; Stanley M Lemon
Journal:  J Biol Chem       Date:  2007-01-25       Impact factor: 5.157

4.  Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study.

Authors:  Janaki Amin; Matthew G Law; Mark Bartlett; John M Kaldor; Gregory J Dore
Journal:  Lancet       Date:  2006-09-09       Impact factor: 79.321

5.  The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-06-28

6.  Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.

Authors:  Silvia Mirandola; Stefano Realdon; Jahangir Iqbal; Martina Gerotto; Francesca Dal Pero; Gladis Bortoletto; Moira Marcolongo; Alessandro Vario; Christian Datz; M Mahmood Hussain; Alfredo Alberti
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

7.  Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation.

Authors:  Uwe J F Tietge; Oliver Selberg; Andreas Kreter; Matthias J Bahr; Matthias Pirlich; Wolfgang Burchert; Manfred J Müller; Michael P Manns; Klaus H W Böker
Journal:  Liver Transpl       Date:  2004-08       Impact factor: 5.799

8.  Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C.

Authors:  T Asselah; N Boyer; M-C Guimont; D Cazals-Hatem; F Tubach; K Nahon; H Daïkha; D Vidaud; M Martinot; M Vidaud; C Degott; D Valla; P Marcellin
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

9.  Hepatitis C virus RNA localization in human carotid plaques.

Authors:  Maria Boddi; Rosanna Abbate; Benedetta Chellini; Betti Giusti; Carlo Giannini; Giovanni Pratesi; Luciana Rossi; Carlo Pratesi; Gian Franco Gensini; Laura Paperetti; Anna Linda Zignego
Journal:  J Clin Virol       Date:  2009-11-05       Impact factor: 3.168

10.  Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.

Authors:  Kathrin Overbeck; Daniel Genné; Alain Golay; Francesco Negro
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

View more
  15 in total

1.  Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people.

Authors:  Antonio De Vincentis; Luisa Costanzo; Umberto Vespasiani-Gentilucci; Antonio Picardi; Stefania Bandinelli; Luigi Ferrucci; Raffaele Antonelli Incalzi; Claudio Pedone
Journal:  Dig Liver Dis       Date:  2019-02-03       Impact factor: 4.088

Review 2.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

Review 3.  Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.

Authors:  Umberto Vespasiani-Gentilucci; Giovanni Galati; Paolo Gallo; Antonio De Vincentis; Elisabetta Riva; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

4.  rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.

Authors:  Daniel Pineda-Tenor; Juan Berenguer; María A Jiménez-Sousa; Ana Carrero; Mónica García-Álvarez; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Cristina Diez; María Guzmán-Fulgencio; Amanda Fernández-Rodríguez; Salvador Resino
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-29       Impact factor: 2.205

Review 5.  Assessing cardiovascular risk in hepatitis C: An unmet need.

Authors:  Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Hepatol       Date:  2015-09-08

Review 6.  Metabolic alterations and hepatitis C: From bench to bedside.

Authors:  Ming-Ling Chang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

7.  Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies.

Authors:  Qi-Tao Huang; Li-Lin Hang; Mei Zhong; Yun-Fei Gao; Man-Ling Luo; Yan-Hong Yu
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  Inhibition of IRS-1 by hepatitis C virus infection leads to insulin resistance in a PTEN-dependent manner.

Authors:  Ting-ting Gao; Zhao-ling Qin; Hao Ren; Ping Zhao; Zhong-tian Qi
Journal:  Virol J       Date:  2015-02-03       Impact factor: 4.099

Review 9.  Hepatitis C Virus, Insulin Resistance, and Steatosis.

Authors:  Dominik Kralj; Lucija Virović Jukić; Sanja Stojsavljević; Marko Duvnjak; Martina Smolić; Ines Bilić Čurčić
Journal:  J Clin Transl Hepatol       Date:  2016-03-15

Review 10.  Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C Virus.

Authors:  Theodoros Voulgaris; Vassilios A Sevastianos
Journal:  Hepat Res Treat       Date:  2016-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.